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Abstract
Background: The interaction of circulating microparticles (MPs) with immune cells in systemic lupus erythematosus
(SLE) is sparsely investigated. We examined the ability of MPs from SLE patients to induce production of reactive
oxygen species (ROS) and degranulation of polymorphonuclear leukocytes (PMNs).
Methods: Plasma MPs, leukocytes and sera isolated from 20 SLE patients and 10 healthy controls were mixed in
different combinations, with or without lipopolysaccharide (LPS), and incubated for 30 min. Dihydrorhodamine 123
was used to measure ROS production by flow cytometry. The ability of immunoglobulin G (IgG) isolated from five
SLE patients to increase MP-induced production of ROS by PMNs was tested. Cell supernatants were analysed for
content of primary, secondary and tertiary granule components by Luminex assays.
Results: MPs from SLE patients promoted ROS production by PMNs, and enhanced LPS-induced ROS production and
release of primary granules by PMNs, when added to samples of autologous leukocytes and serum. In a similar
autologous setting, MPs from healthy controls enhanced LPS-induced ROS production by PMNs. When leukocytes from
a healthy control were stimulated with autologous MPs in the presence of various sera, SLE patient serum promoted
ROS production and release of primary and secondary granules by PMNs. A role for antibodies in this respect was
indicated by the observation that supplementation of normal serum with IgG from SLE patients promoted MP-induced
ROS production by healthy PMNs. Moreover, when various MPs were incubated with leukocytes and serum from a
healthy control, patient-derived MPs induced more ROS production by PMNs than did healthy control-derived MPs.
Conclusions: SLE patients display increased ROS production and degranulation by PMNs in response to MPs, which
partly depends on serum components, including antibodies, MP properties and hyper-responsiveness of the PMNs per se.
Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease of unknown aetiology, characterized by
the presence of a multitude of circulating autoantibodies
against components of cellular origin which includes a
variety of anti-nuclear antibodies. There is no consensus
on how nuclear antigens are presented to the immune sys-
tem, but circulating microparticles (MPs) carrying cellular
constituents are among the main candidates [1]. MPs are
small extracellular vesicles in the range of 0.1–1 μm, shed
from apoptotic or activated cells by blebbing of the cell
membrane. They have known effects on thrombosis, vas-
culature and inflammation [2], and alterations in MP con-
centration and composition have been linked to
autoimmunity, especially SLE [3, 4]. Detection of autoanti-
bodies binding to nuclear material on the surface of MPs
in SLE and findings suggestive of MP deposition on the
glomerular basement membrane in patients with lupus
nephritis indicate that MPs play a central pathogenic role
in SLE [5, 6]. Whereas many studies have focused on sur-
face properties of MPs, including autoantigenic properties,
the interactions between MPs and immune cells, and the
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subsequent consequences in terms of cellular functions,
are sparsely described.
Evidence of involvement of polymorphonuclear leuko-
cytes (PMNs) in the pathogenesis of SLE has become in-
creasingly established during the past decade: PMNs from
SLE patients show enhanced apoptosis and production of
neutrophil extracellular traps (NETosis) [7] and decreased
production of reactive oxygen species (ROS) after stimula-
tion with phorbol-12-myristate-13-acetate (PMA) [8], as
well as with complement-opsonized immune complexes
(ICs) [9]. However, this may be explained by a generalized
hyper-reactivity of SLE PMNs [7, 10, 11] and death of the
most reactive PMNs [8]. Increased oxidative stress has been
linked with SLE and may contribute to immune dysregula-
tion including increased occurrence of post-translational
modifications leading to modified self-antigens and auto-
antibody production [12]. Further, antioxidant treatment
has been shown to reduce both oxidative stress and symp-
tom severity in SLE [13, 14].
The main receptors involved in PMN ROS production
elicited by complement-opsonized ICs are complement
receptor 3 (CR3, CD11b/CD18) in concert with IgG-Fc
receptor (FcγR) II [15, 16]. Stimulation with
complement-opsonized ICs also leads to complement-
receptor-independent release of elastase from azurophi-
lic (primary) granules and CR3-mediated release of
lactoferrin from specific (secondary) granules [15]. Other
markers of primary and secondary granules are myelo-
peroxidase (MPO) and neutrophil gelatinase-associated
lipocalin (NGAL), respectively [17]. Whereas FcγRII is
involved in both ROS generation and degranulation,
engagement of FcγRIII seemingly results only in
degranulation [18].
We recently showed that incubation of MPs from SLE
patients with autologous leukocytes leads to deposition
of MPs on PMNs, which is greater than the correspond-
ing deposition of MPs from healthy controls on autolo-
gous PMNs [19]. The implications of this deposition for
PMN function are largely unknown, and existing studies
have primarily investigated effects of in-vitro-generated
MPs [20, 21]. For example, one study showed increased
phagocytic activity and CR3 expression by PMNs after
incubation with platelet-derived, in-vitro-generated MPs
[20]. The immune stimulatory potential of plasma MPs
has been investigated by Dieker et al. [22], who demon-
strated that MPs from SLE patients primed neutrophils
for LPS-induced NETosis. Given MPs’ similarity with
ICs in terms of carriage of IgG and complement compo-
nents [19, 23], we speculated that they may be capable
of eliciting ROS production and degranulation of PMNs.
MPs might thereby contribute to the increased oxidative
stress in SLE patients. In this study, we investigated the
ability of MPs to induce ROS production and degranula-
tion in PMNs, and we determined whether these
responses differ between SLE patients and healthy
controls.
Methods
SLE patients and healthy controls
SLE patients were included from our inpatient and out-
patient rheumatology clinic and fulfilled internationally
accepted classification criteria [24, 25]. Disease activity
was described using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI)-2 K 30 days [26] and
other available clinical information. The healthy controls
included were anonymous blood donors at the Blood
Bank of Copenhagen University Hospital, Rigshospitalet.
The study was approved by the regional scientific ethics
committee (protocol no. H-1-2013-046). For experi-
ments including only SLE and healthy control sera or
MPs as variables, frozen samples from this study and an
earlier study [19] were used. Patient characteristics are
presented in Table 1.
Purification of MPs
MPs were purified as described previously [19]. In brief,
6 ml of blood was collected in a K2EDTA tube (Vacu-
ette; Greiner Bio-one GmbH, Kremsmünster, Austria) by
venous puncture. After transfer of 600 μl of the blood to
Table 1 Characteristics of included SLE patients and HCs
Fresh cells, serum and
MPs
Frozen serum
and MPs
SLE patients 20 28
Age, median (range) 45 (22–64) 42 (22–69)
Sex, number (%) of
females
17 (85) 24 (86)
Disease manifestations at study inclusion, number (%) of patients
Renal disease 2 (10) 8 (29)
Vasculitis 2 (10) 3 (11)
Arthritis 2 (10) 3 (11)
Interstitial lung
disease
1 (5) 0 (0)
Haemolysis 1 (5) 1 (4)
Alopecia 3 (15) 1 (4)
Rash 2 (10) 3 (11)
Mucosal ulcers 3 (15) 3 (11)
Leucopenia 1 (5) 1 (4)
Serositis 0 (0) 1 (4)
Thrombocytopenia 0 (0) 1 (4)
SLEDAI, median (range) 4 (0–12) 5 (0–18)
HCs 10 11
Age, median (range) 33.5 (25–63) 34 (24–54)
Sex, number (%) of
females
6 (60) 9 (82)
HC healthy control, SLE systemic lupus erythematosus, SLEDAI Systemic
Lupus Erythematosus Disease Activity Index
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other tubes for the purification of leukocytes, as de-
scribed later, the blood was centrifuged at 1800 × g for
10 min at 37 °C and supernatants were transferred to a
new tube and centrifuged at 3000 × g for 10 min at 37 °C
for removal of platelets. The platelet-poor plasma was
then filtered through a 1.2-μm syringe filter (Minisart;
Sartorius, Göttingen, Germany) and divided into aliquots
of 460 μl. Each aliquot was added 10% RPMI-1640
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA)
and ultracentrifuged twice at 19,000 × g for 30 min at
21 °C; the first step was followed by washing in RPMI,
and the last step was followed by resuspension in RPMI
at a total volume of 100 μl.
Purification of immunoglobulin from SLE patients
A pool of sera from five SLE patients was transferred to
an Illustra Column PD-10 (GE Healthcare, Chicago, IL,
USA) containing 4 ml rProtein A Sepharose Fast Flow
(Amersham Biosciences, GE Healthcare), and after stand-
ing 10 min at 4 °C the column was rinsed with 4 × 10 ml
of Dulbecco’s phosphate buffered saline (PBS; Biological
Industries, Cromwell, CT, USA). After adding 5 × 1 ml of
glycine buffer (0.2 M, pH 2.4), the sample was transferred
to a Vivaspin 15R10 kD (Sartorius) and centrifuged at
3000 × g for 10 min at 22 °C. After washing with 5 ml
PBS, the centrifugation was repeated and the remaining
500 μl sample was resuspended in a total of 2 ml PBS.
Lastly, the sample was transferred to a Float-A-Lyzer G2
Dialysis Device 50 kD (Spectrum Laboratories Inc.,
Rancho Dominguez, CA, USA) and dialysed over night
against 500 ml PBS that was renewed once. The protein
concentration of the dialysate was measured to be
10.7 mg/ml using a Spectro Star Nano (BMG Labtech,
Ortenberg, Germany) with an LVis Plate (BMG Labtech).
Stimulation of PMNs
Aliquots of 200 μl K2EDTA blood were stored at 4 °C
for approximately 1 hour, until the last step of the MP
purification. Afterwards, the red blood cells were re-
moved by 15 min of lysis in a 1:10 dilution of BD
Pharm Lyse Lysing Buffer (BD Biosciences, San Jose,
CA, USA), according to the manufacturer’s instruc-
tions. After lysis, the solution was centrifuged twice at
300 × g for 5 min at room temperature; the first step
was followed by washing in Dulbecco’s Phosphate Buff-
ered Saline (Thermo Fisher Scientific), and the final
volume was adjusted to 200 μl. Aliquots of 36.6 μl of
the cell solution were incubated for 30 min at 37 °C in
RPMI-1640 containing 25% (v/v) serum at a total vol-
ume of 200 μl with no stimulation, 10 μg/ml E. Coli
LPS (Sigma, Merck, Kenilworth, NJ, USA), 20 μl of
purified MP solution, 10 μg/ml LPS plus 20 μl of puri-
fied MP solution or 60 nM PMA (Sigma). All samples
contained 0.66 mM dihydrorhodamine 123 (DHR)
(Molecular Probes, Thermo Fisher Scientific), which is
oxidized intracellularly by H2O2 to fluorescent rhoda-
mine 123. An additional aliquot was incubated without
DHR to measure background fluorescence. After incu-
bation, the samples were washed in cold PBS and cen-
trifuged at 740 × g for 10 min at 4 °C. Supernatants
were removed for analysis of granule content (see
later) and cells were incubated with anti-CD15 APC
(BD Biosciences) for 30 min at 4 °C. The LIVE/DEAD
Fixable Near-IR Dead Cell Stain (Molecular Probes)
was used to discriminate between live and dead PMNs.
After a similar wash, cells were analysed by flow cy-
tometry using a BD FACSCanto II (BD Biosciences).
Additional file 1 shows the gating strategy.
In another series of experiments, leukocytes from
SLE patients and healthy controls were stimulated with
the previously described stimuli in the presence of ei-
ther autologous serum or normal human serum (NHS)
from of a pool of sera from blood group AB-positive
donors (Sigma Aldrich, Merck). In a third series, leu-
kocytes from a single healthy donor were stimulated in
the presence of various sera from SLE patients or
healthy controls. In a fourth series of experiments,
leukocytes from healthy controls were stimulated in
RPMI-1640 containing autologous serum supple-
mented with IgG purified from sera of five SLE
patients, as already mentioned, or with normal IgG for
intravenous use (IVIg; CSL Behring, King of Prussia,
PA, USA). In a fifth series of experiments, leukocytes
from a healthy control, suspended in RPMI containing
autologous serum, were stimulated with MPs from
various SLE patients or healthy controls. Table 2
presents an overview of the different experimental
conditions applied.
Table 2 Overview of experiments
Experiment/Figure PMNs Serum MPs LPS IgG
1 Autologous SLE and HC Autologous SLE and HC Autologous SLE and HC +/– –
2 Autologous SLE and HC SLE/normal human serum Autologous SLE and HC +/– –
3 HC SLE/HC HC + –
4 HC HC HC +/– SLE/normal
5 HC HC SLE/HC + –
HC healthy control, IgG immunoglobulin G, LPS lipopolysaccharide, MP microparticle, PMN polymorphonuclear leukocyte, SLE systemic
lupus erythematosus
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Measurement of degranulation
Supernatants were kept frozen at –80 °C until analysis of
granule content using R&D Magnetic Luminex Screen-
ing Assays (R&D Systems, Minneapolis, MN, USA) on a
Luminex Bio-Plex® 200 system (Bio-Rad Laboratories,
Hercules, CA, USA). The content of MPO from primary
granules was analysed with the aid of a one-plex MPO,
and the content of NGAL and gelatinase (MMP-9) from
secondary and tertiary granules, respectively, was ana-
lysed using a two-plex MMP-9 and Lipocalin-2/NGAL.
Analysis of the fluorescence data was done using Bio-
Plex Manager 6.0 Software (Bio-Rad Laboratories). The
experiments were carried out according to the manufac-
turer’s instructions.
Statistical analysis
Because the study data were not normally distributed,
non-parametric statistical methods were applied. The
effects of different stimuli were investigated using the
Wilcoxon matched-pairs signed rank test. Comparisons
between groups were done using the Mann–Whitney U
test, and correlations were determined using Spear-
man’s correlation coefficient (rs). The differences be-
tween ratios were calculated using a Wilcoxon signed
rank test where the difference from a theoretical value
(=1) was tested.
Results
The patient material for this study was sampled on two
separate occasions producing 20 samples to be used im-
mediately after sampling (fresh) and then 28 samples of
serum and platelet poor plasma to be frozen. Fourteen
of the patients with frozen samples had been included in
a previous study [19]. Clinical and demographical char-
acteristics of the included SLE patients and healthy con-
trols are presented in Table 1.
ROS production and degranulation of PMNs stimulated
with MPs and/or LPS
We examined ROS production by PMNs in fresh leukocyte
preparations by flow cytometry using dihydrorhodamine
123 as a probe. The cells were stimulated with autologous
MPs, alone or in combination with LPS, or with PMA
(Fig. 1a–d). Within samples, the PMNs often showed het-
erogeneous ROS production after these stimuli. Incuba-
tion with MPs induced a significant increase in the
production of ROS by PMNs from SLE patients but not
by PMNs from healthy controls (Fig. 1e). When PMNs
were stimulated with LPS, co-stimulation with MPs in-
creased the production of ROS significantly in PMNs from
both SLE patients and healthy controls (Fig. 1e).
We reasoned that the serum C3 level was a disease
activity marker related to IC and MP clearance capacity
in vivo. We therefore subdivided SLE patients into two
groups with circulating C3 levels > 1 g/l and ≤ 1 g/l, re-
spectively. Notably, ROS production by PMNs from pa-
tients with low circulating C3 levels exceeded that of
both PMNs from patients with high C3 levels and that
of healthy control PMNs after stimulation with MPs
(Fig. 1f ). An indication that this was due to hyper-
responding PMNs in SLE patients came from the finding
that PMNs from SLE patients produced significantly
more ROS than PMNs from healthy controls after
stimulation with PMA (p = 0.0011) (Fig. 1g). Using this
stimulus, no difference was observed between high C3
and low C3 subgroups.
We also examined degranulation, as another measure
of PMN activation, and found that addition of autolo-
gous MPs to LPS-stimulated PMNs resulted in a sig-
nificant increase in the release of MPO from primary
granules in the SLE group, but not in the healthy con-
trol group (Fig. 2h). PMN degranulation of secondary
or tertiary granules was not observed (see Additional
file 2A, B).
Influence of serum on ROS production and degranulation
of PMNs
Having observed that PMNs from SLE patients showed
higher responses to MPs than PMNs from healthy con-
trols when autologous serum was present, we wished to
examine to what extent this difference was determined
by serum factors including autoantibodies and comple-
ment components. We therefore compared the produc-
tion of ROS observed in autologous serum with that
observed in NHS.
The ROS production induced by MPs and LPS was
significantly higher in the presence of the SLE patients’
own serum than in the presence of NHS, as shown in
Fig. 2a (p = 0.031). Conversely, the PMA-induced pro-
duction of ROS by PMNs was decreased when SLE
serum was present (p = 0.023).
An indication that consumption of complement in
SLE serum influenced ROS production after stimula-
tion of PMNs with MPs and LPS came from the find-
ing that the SLE:NHS ratio for ROS production tended
to correlate positively with the C3 content in the pa-
tients’ serum (rs =0.75, p = 0.066) (Fig. 2b). By contrast,
no correlation was observed with the serum content of
antibodies to double-stranded deoxyribonucleic acid
(dsDNA) (rs = –0.22, p = 0.64) or with SLEDAI values
(rs = –0.31, p = 0.50). The origin of serum present dur-
ing the stimulation with MP, alone or in combination
with LPS, did not influence the PMN degranulation
(see Additional file 2C–E).
To test directly the effect of serum on MP-induced ROS
production by PMNs, leukocytes from a single healthy
control were stimulated with a combination of autologous
MPs and LPS in the presence of heterologous sera derived
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from 20 patients (10 of whom had active disease) and 10
healthy controls (Fig. 3). Under these circumstances, PMN
production of ROS was greatly promoted by sera from SLE
patients, irrespective of the C3 content, compared with
sera from healthy controls (p = 0.0034) (Fig. 3a). The ROS
production correlated positively with the level of circulat-
ing anti-dsDNA antibodies in SLE serum (rs = 0.496, p =
0.0031) (Fig. 3b) but not with the level of circulating C3
(see Additional file 3). Release of both primary and second-
ary granules increased when SLE serum with high C3
content was present (Fig. 3c, d). A similar tendency was
observed for the release of tertiary granules (Fig. 3e).
Influence of antibodies on MP-induced ROS production
by PMNs
To investigate the influence of antibodies in the
serum-mediated enhancement of ROS production,
leukocytes from healthy controls were stimulated
with autologous MPs, alone or in combination with
LPS, in the presence of autologous serum
supplemented with various amounts of either IgG
purified from SLE patients or IVIg purified from
healthy donors. As shown in Fig. 4, IgG from SLE
patients strongly promoted ROS production by
PMNs.
Fig. 1 PMN ROS production and degranulation induced by autologous MPs and/or LPS. Leukocytes from 20 SLE patients and 10 healthy
controls were incubated with (a) autologous MPs, (b) LPS, (c) a combination of autologous MPs and LPS or (d) PMA for 30 min in the
presence of autologous serum and DHR, a probe for H2O2 production. Fluorescent oxidation product rhodamine 123 contained in PMNs
staining positive for CD15 and negative for the dead cell marker near infrared was measured by flow cytometry and expressed as median
fluorescence intensity (MFI) units. (e) Increase in ROS production after addition of MPs or MPs in combination with LPS. PMN production of
ROS after stimulation with (f) MPs or (g) PMA, adjusted for background activity (of unstimulated cells), is shown for healthy controls and SLE
patients with high and low levels of circulating complement C3, respectively. (h) Concentration of the primary granule protein
myeloperoxidase (MPO) released into the cell supernatants. HC healthy control, LPS lipopolysaccharide, MP microparticle, ROS reactive
oxygen species, SLE systemic lupus erythematosus, Unstim unstimulated
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Fig. 2 Influence of serum on MP-induced ROS production by SLE PMNs. Purified leukocytes from eight SLE patients, six of whom had SLEDAI > 5,
were incubated with DHR and stimulated for 30 min at 37 °C with autologous MPs alone or in combination with LPS, or with PMA, in a medium
containing 25% v/v autologous serum or a pool of NHS. The resulting ROS production by PMNs was analysed by flow cytometry, and the ratio
between median fluorescence intensity (MFI) values obtained in the presence of SLE serum above that obtained in the presence of NHS was
calculated after adjustment for background (unstimulated cells). Ratios from three experiments were excluded because either the numerator or
denominator was negative. (a) Ratios between MFI values observed after stimulation with MPs and LPS in the presence of autologous serum
above that observed in the presence of NHS. Bars represent median ratios. (b) Correlation between the ratio and circulating levels of C3 in
samples stimulated with a combination of MPs and LPS. Dotted line represents the lower limit of the normal range. LPS lipopolysaccharide,
MP microparticle, PMA phorbol-12-myristate-13-acetate, SLE systemic lupus erythematosus, Unstim unstimulated
Fig. 3 MP-induced ROS production and degranulation of PMNs in the presence of heterologous sera. Leukocytes from a healthy blood group 0
donor were suspended in a medium containing 25% v/v of serum from 20 SLE patients and 10 healthy controls (see Table 1, frozen samples).
DHR was used as probe for H2O2, and the cells were stimulated with autologous MPs in combination with LPS for 30 min at 37 °C before flow
cytometry. (a) Median fluorescence intensity (MFI) after subtraction of background fluorescence (unstimulated cells). SLE patients were divided
into two groups with circulating C3 levels > 1 g/l and≤ 1 g/l, respectively. (b) Correlation between MFI values and anti-dsDNA antibody levels of
patient sera. (c–e) Degranulation measured in the corresponding cell supernatants as the content of myeloperoxidase (MPO) from primary
granules, neutrophil gelatinase-associated lipocalin (NGAL) from secondary granules and matrix metallopeptidase 9 (MMP-9) from tertiary granules.
Bars represent median values. dsDNA double-stranded DNA, HC healthy control, SLE systemic lupus erythematosus
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Influence of MPs on ROS production and degranulation
by normal PMNs
To examine whether MPs from SLE patients and
healthy controls differed in their capacity to induce
production of ROS in PMNs, we compared the ROS
production by normal PMNs stimulated with LPS and
MPs derived from 20 SLE patients and 10 healthy con-
trols. MPs from SLE patients induced more ROS pro-
duction than did MPs from healthy controls, and this
was statistically significant for the total group of SLE
patients (p = 0.006) and for those with high disease
activity, as measured by the level of circulating C3 (p
= 0.0008), but not for those with a correspondingly low
disease activity (Fig. 5a). MPs from SLE patients and
healthy controls did not differ in their ability to induce
release of primary or tertiary granule contents by
PMNs when co-incubated with LPS (see Additional file
2F, G). However, MPs from SLE patients with comple-
ment activation tended to induce release of more
NGAL from secondary granules than MPs from
healthy controls (Fig. 5b).
Discussion
The objective of this study was to examine the ability of
plasma-derived MPs to activate PMNs for production of
ROS and degranulation, and to compare these effects in
SLE patients and healthy controls.
A key finding was that MPs from SLE patients in-
duced ROS production in the patients’ own PMNs
suspended in autologous serum, thus resembling in-
vivo conditions. The same was not observed when
PMNs from healthy controls suspended in autologous
serum were stimulated with MPs purified from their
own blood. This supports the notion that MPs medi-
ate pro-inflammatory effects in SLE. The MP-induced
ROS production was the most pronounced in patients
with low levels of circulating C3. As low C3 levels
may reflect complement activation in vivo, these are
generally considered markers of active disease in SLE
patients [27, 28].
At least three factors may have contributed to the
increased responsiveness of SLE PMNs to MPs in the
autologous setting: the PMNs of SLE patients, particu-
larly those with low C3 levels, may have been primed in
vivo; serum components (e.g. opsonizing autoantibodies
Fig. 4 Influence of exogenously added IgG on MP-induced ROS
production by PMNs. Leukocytes purified from three healthy blood
group 0 donors were stimulated with autologous MPs, alone (open
symbols) or in combination with LPS (closed symbols), in the presence
of autologous serum supplemented with various amounts of IgG from
SLE patients (SLE IgG) or healthy donors (IVIg). DHR was used as probe
for H2O2 production. Shown is the resulting median fluorescence inten-
sity (MFI) of PMNs, as measured by flow cytometry. Symbols represent
average and error bars represent range. IgG immunoglobulin G, LPS
lipopolysaccharide, MP microparticle, SLE systemic lupus erythematosus
Fig. 5 Influence of SLE and healthy control MPs on MP-induced ROS production and degranulation of PMNs. Leukocytes from a healthy control were
suspended in a medium containing 25% v/v of normal human serum. DHR was added to the suspensions, and the cells were stimulated with LPS in
combination with MPs from 20 SLE patients and 10 healthy controls for 30 min at 37 °C before flow cytometry. (a) The resulting median fluorescence
intensity (MFI) after subtraction of background fluorescence (unstimulated cells). Bars represent median values. Comparisons between groups using
Mann–Whitney U test (b) Content of neutrophil gelatinase-associated lipocalin (NGAL) in the supernatants of leukocytes stimulated with MPs and LPS
in combination shown as median values after subtraction of the background (unstimulated cells). HC healthy control, SLE systemic lupus erythematosus
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or increased levels of anaphylatoxins or pro-
inflammatory cytokines) may promote PMN activation;
and the MPs per se may have increased capacity for
PMN activation (e.g. due to tagging with complement
fragments [19] or antibodies [23]).
An indication that patient PMNs had been primed in
vivo came from our finding that PMNs from SLE
patients showed increased responsiveness to PMA. In
accordance, Dieker et al. [22] demonstrated increased
NETosis by SLE PMNs after stimulation with in-vivo-
generated MPs and LPS. Our findings are in contrast
with previous findings of decreased ROS production
after stimulation of PMNs from SLE patients with
PMA [8] or with complement-opsonized ICs [9]. The
former study used PMNs stored for up to 24 hours
prior to the experiment, which might have caused
death of the most pre-activated PMNs. SLE is associ-
ated with increased PMN death via both apoptosis and
NETosis [7]. Increased propensity of PMNs from SLE
patients to produce ROS may, at least in part, be ex-
plained by decreased expression of FcγRII, which in-
hibits ROS production [29, 30].
The influence of serum factors on MP-induced PMN
responses was assessed in three ways in this study.
Firstly, the response of SLE PMNs to autologous MPs
in the presence of autologous serum was compared
with that observed in the presence of NHS. Secondly,
PMNs from a single healthy donor were stimulated
with autologous MPs in combination with LPS, in
a medium containing serum from 20 different SLE pa-
tients and 10 healthy controls. Both approaches re-
vealed that SLE sera promoted ROS production by
PMNs, and the latter revealed an association between
MP-induced ROS production and circulating anti-
dsDNA levels. Thirdly, a role for antibodies in the
serum-mediated enhancement of ROS production by
PMNs was demonstrated by the finding that IgG from
SLE serum markedly increased the ROS production in-
duced by MPs alone or in combination with LPS. Pre-
vious studies have shown that SLE serum is able to
induce ROS production by healthy PMNs without any
additional stimuli, and because this also applied to
complement-depleted serum, autoantibodies were as-
sumed to be the main stimulant [31, 32].
We also examined the influence of MPs per se on
PMN ROS production. The combination of LPS and
MPs from patients with low circulating C3 levels in-
duced more ROS than LPS in combination with MPs
from healthy controls or patients with relatively high
C3 levels. Low levels of circulating C3 presumably re-
flect complement consumption as a result of comple-
ment activation in vivo. We have not measured C3 and
IgG on MPs derived from the NHDs and SLE patients
included in this study, but we have in our unit
previously examined the composition of MPs from
healthy donors and SLE patients using the same MP
purification technique: We found that MPs from SLE
patients had increased amounts of C3 fragments and
IgG on the surface [19, 23], and increased deposition
of complement on MPs has been associated with dis-
ease activity [33]. Moreover, increased amounts of IgG
on the MP surface are related to disease activity [23].
This IgG deposition may, via interaction with FcRs in
the same manner as ICs [29], further enhance the abil-
ity of SLE MPs to induce ROS in PMNs. We therefore
find it very likely that in-vivo tagging of MPs from SLE
patients with complement and IgG is responsible for
the increased ability of these MPs to induce produc-
tion of ROS by PMNs.
The PMN degranulation did not differ between
SLE patients and healthy controls in the autologous
setting. Stimulation with MPs in combination with
LPS induced release of primary granules, as mea-
sured by MPO release, in both groups, but only in
the SLE group did MPs enhance LPS-stimulated
MPO release. An indication that SLE serum may
contain factors which promote release of both pri-
mary and secondary granules came from the finding
that the combination of MPs and LPS seemed to in-
duce release of more MPO and NGAL in the pres-
ence of SLE patient serum containing normal C3
levels than in the presence of SLE serum containing
low C3 levels. It is likely that the factor in SLE
serum promoting degranulation is autoantibodies.
Activation of FcγRIII plays an important role in de-
granulation [29]. However, the fact that degranulation
was related to the presence of C3 also corresponds
well with the co-stimulatory role demonstrated for
CR3 in induction of degranulation [29].
Limitations of this study are the low numbers of highly
active SLE patients (including those with nephritis) and
the lack of a disease control group. The number of in-
cluded patients was limited. Nevertheless, we were able
to demonstrate clear differences between SLE patients
and healthy controls, and between patients with high
and low circulating C3 levels. Further research should
include more mechanistic studies, such as investigation
of the role of complement receptors and ICs bound to
the MP surface in MP-induced stimulation of PMNs.
Conclusions
The present study demonstrates that PMNs from SLE
patients are hyper-responsive to stimulation with MPs
or PMA, and that MPs, serum and purified IgG from
SLE patients each promote ROS production by PMNs.
These factors may all contribute to driving ROS-
dependent inflammation in SLE.
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Additional files
Additional file 1: Is a figure showing flow cytometric gating of live
PMNs. PMNs in samples of leukocytes were identified on the basis of (A)
forward and side scatter characteristics, (B) gating for single cells and (C)
positive staining for CD15 and negative staining for the dead cell marker
near infrared (IR). (JPG 203 kb)
Additional file 2: Is a figure showing degranulation of PMNs stimulated
with MPs in the presence of serum. (A, B) Leukocytes from 20 SLE patients
and 10 healthy controls were incubated with autologous MPs, LPS or a
combination of autologous MPs and LPS for 30 min in the presence of
autologous serum. Concentration of (A) neutrophil gelatinase-associated
lipocalin (NGAL) from secondary granules and (B) matrix metallopeptidase 9
(MMP-9) from tertiary granules in cell supernatants. (C–E) Leukocytes from
eight SLE patients were incubated for 30 min at 37 °C with autologous MPs
alone or in combination with LPS, or with PMA, in a medium containing
25% v/v autologous serum or normal human serum (NHS). Concentrations
of (C) myeloperoxidase (MPO) from primary granules, (D) NGAL from sec-
ondary granules and (E) MMP-9 from tertiary granules in the presence of
SLE serum above that observed when NHS was present (SLE:normal) and
after subtraction of background (unstimulated cells). (F, G) Leukocytes from
a healthy control were incubated with LPS in combination with MPs from
20 SLE patients and 10 healthy controls in the presence of NHS for 30 min
at 37 °C. Contents of (F) MPO and (G) MMP-9 in the supernatants shown as
median values after subtraction of background (unstimulated cells). Bars rep-
resent median values. Granule contents measured by Luminex assays. (JPG
1139 kb)
Additional file 3: Is a figure showing MP-induced ROS production by
PMNs in the presence of SLE sera. Leukocytes from a healthy blood
group 0 donor were suspended in a medium containing 25% v/v of
serum from 20 SLE patients (see Table 1, frozen samples). DHR was used
as probe for H2O2, and the cells were stimulated with autologous MPs in
combination with LPS for 30 min at 37 °C before flow cytometry.
Correlation between the resulting median fluorescence intensity (MFI)
after subtraction of background fluorescence (unstimulated cells) and
levels of circulating anti-dsDNA antibodies. (JPG 175 kb)
Abbreviations
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IgG: Immunoglobulin G; LPS: Lipopolysaccharide; MP: Microparticle;
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myristate-13-acetate; PMN: Polymorphonuclear leukocyte; ROS: Reactive
oxygen species; SLE: Systemic lupus erythematosus
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